Under the Paperwork Reduction Act of 1995, no persons are required

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10713451
Filing Date		2003-11-14
First Named Inventor	Charles A. Gressett, Jr.	
Art Unit		3752
Examiner Name	Unknown	
Attorney Docket Numb	er	NOR-993C

					,						
					U.S.	PATENTS			Remove		_
Examiner Initial*	Cite No	Patent Number	Kind Code ¹			Pages, Columns, Lines where Relevant Passages or Relevan Figures Appear					
	1										
If you wish	h to a	i dd additional U.S. Pater	nt citatio	n inform	ation pl	lease click the	Add button.	_	Add		_
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove		_
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date			Releva		Lines where ges or Relev		
	1										
If you wish	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	d button	n. Add		
				FOREIG	SN PAT	TENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country	y Code ²	Kind Code ⁴		Name of Patentee Applicant of cited Document	e or	where Rel	or Relevant	75
	1										Г
If you wish	h to a	dd additional Foreign Pa	atent Do	cument	citation	information pl	ease click the Add	button	Add		_
		_	NON	4-PATE	NT LITE	RATURE DO	CUMENTS		Remove		Т
Examiner Initials*	Cite No	Include name of the au (book, magazine, journ publisher, city and/or of	nal, seria	al, symp	osium,	catalog, etc), o					Τs

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)					
		Filing Date		2003-11-14	
		First Named Inventor	First Named Inventor Charles A. Gressett, Jr.		
		Art Unit		3752	
		Examiner Name Unknown		own	
		Attorney Docket Numb	er	NOR-993C	

10713451

Application Number

	European Falcin, Olinos, European Falcin,	ocardi non concepcional di Papinanon No. (2200000), 2000 11 20					
If you wish to add additional non-patent literature document citation information please click the Add button Add							
EXAMINER SIGNATURE							
Examiner Signa	iture	Date Considered					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Patent Documents at wore USPTO_GOV or MPEP 991.04. If Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). If Yes Jupanese patent documents, his noticeation of the year of the eitigan of the Empire must preced the sensit number of the platent document.

Second ST.3. If Yes Jupanese patent documents, his noticeation of the year of the eitigan of the Empire must preced the sensit number of the platent document.

English improace treatment on standard. In place a recordant on the document under WIPO Standard ST.48 (Septions). "Applicated to place a recordant on the foreign that place a record not not place a record not place a record not place a record not not place a record not place

RMATION DISCLOSURE EMENT BY APPLICANT r submission under 37 CFR 1.99)	Application Number		10713451	
	Filing Date		2003-11-14	
	First Named Inventor Charl		ries A. Gressett, Jr.	
	Art Unit		3752	
	Examiner Name Unkn		nown	
	Attorney Docket Number		NOR-993C	

CERTIFICATION STATEMENT

Please see 37 C	FR 1 97	and 1 98 to	make the	annonnista	coloction(c)

That each item of information contained in the information disclosure statement was first cited in any communication \overline{Q} from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

ı			
	That no item of information contained in the information disclasure statement	t was sited in a somm	unication from a

See attached certification statement.

STAT

OR

foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification
after making reasonable inquiry, no item of information contained in the information disclosure statement was known to
any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure
statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

ree set lotti in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Kevin G. Rooney/	Date (YYYY-MM-DD)	2006-01-20
Name/Print	Kevin G. Rooney	Registration Number	36330

This collection of information is required by 37 CFR. 187 and 1.98. The information is required to obtain or retain a benefit by the public which is to lie (and by the USFTO is porcess) an application. Confidentially is generate by \$5.U.S. CI. 20 and 37 CFR. 114. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USFTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Operament of Commence, P. O. Box 1450, Alexandrin, V.S. 2231-1450. DN OTS END FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandrin, V.S. 2231-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is SU U.S. C. (2)(2)(2) (2) famishing of the information solicide is voluntary, and (3) the principal purpuses for which the information is used by the U.S. Patient and Trademan Kolline is to process another examines your submission related to a patient application or patient. If you do not furnish the requested process another examines your submission related to a patient application or patient. If you do not furnish the requested the process another examines your submission related to a patient application or patient. If you do not furnish the requested the process another examines your submission, which may related the process and/or examines your submission, which may related the process and/or examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disease records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S. C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, cuting an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make indemninations a partial individuals.
 - 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CPR 1-14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.